153 related articles for article (PubMed ID: 19182243)
21. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A
Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216
[TBL] [Abstract][Full Text] [Related]
23. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
[TBL] [Abstract][Full Text] [Related]
24. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
26. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
Lubner SJ; Mahoney MR; Kolesar JL; Loconte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD
J Clin Oncol; 2010 Jul; 28(21):3491-7. PubMed ID: 20530271
[TBL] [Abstract][Full Text] [Related]
27. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Arnoletti JP; Frolov A; Eloubeidi M; Keene K; Posey J; Wood T; Greeno E; Jhala N; Varadarajulu S; Russo S; Christein J; Oster R; Buchsbaum DJ; Vickers SM
Cancer Chemother Pharmacol; 2011 Apr; 67(4):891-7. PubMed ID: 20589377
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.
Goss GD; Jonker DJ; Laurie SA; Weberpals JI; Oza AM; Spaans JN; la Porte C; Dimitroulakos J
J Transl Med; 2016 Mar; 14():83. PubMed ID: 27036206
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Dickler MN; Rugo HS; Eberle CA; Brogi E; Caravelli JF; Panageas KS; Boyd J; Yeh B; Lake DE; Dang CT; Gilewski TA; Bromberg JF; Seidman AD; D'Andrea GM; Moasser MM; Melisko M; Park JW; Dancey J; Norton L; Hudis CA
Clin Cancer Res; 2008 Dec; 14(23):7878-83. PubMed ID: 19047117
[TBL] [Abstract][Full Text] [Related]
30. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
You B; Brade A; Magalhaes JM; Siu LL; Oza A; Lovell S; Wang L; Hedley DW; Nicacio LV; Chen EX
Invest New Drugs; 2011 Oct; 29(5):996-1003. PubMed ID: 20454832
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Bauman J; Verschraegen C; Belinsky S; Muller C; Rutledge T; Fekrazad M; Ravindranathan M; Lee SJ; Jones D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):547-54. PubMed ID: 21901396
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
Langenberg MH; Witteveen PO; Lankheet NA; Roodhart JM; Rosing H; van den Heuvel IJ; Beijnen JH; Voest EE
Neoplasia; 2010 Feb; 12(2):206-13. PubMed ID: 20126478
[TBL] [Abstract][Full Text] [Related]
34. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
[TBL] [Abstract][Full Text] [Related]
35. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.
Steele N; Anthony A; Saunders M; Esmarck B; Ehrnrooth E; Kristjansen PE; Nihlén A; Hansen LT; Cassidy J
Br J Cancer; 2012 Feb; 106(5):793-8. PubMed ID: 22315057
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
Arnold D; Höhler T; Dittrich C; Lordick F; Seufferlein T; Riemann J; Wöll E; Herrmann T; Zubel A; Schmoll HJ
Ann Oncol; 2008 Aug; 19(8):1442-1449. PubMed ID: 18441330
[TBL] [Abstract][Full Text] [Related]
38. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
[TBL] [Abstract][Full Text] [Related]
39. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
40. A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Yoh K; Doi T; Ohmatsu H; Kojima T; Takahashi H; Zenke Y; Wacheck V; Enatsu S; Nakamura T; Turner K; Uenaka K
Invest New Drugs; 2016 Oct; 34(5):584-95. PubMed ID: 27422720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
